Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
BOSTON SCIENTIFIC CORP
Boston Scientific has appointed Joe Fitzgerald as the new Chief Operating Officer, effective January 1, 2027, and will reorganize into three reportable segments—Interventional Therapies, Rhythm Solutions, and MedSurg—to enhance operational efficiency. Additionally, the company announced that Mark Bickel will become the new Chief Accounting Officer, effective March 1, 2027.…more
BOSTON SCIENTIFIC CORP
Arthur C. Butcher, Executive Vice President and Group President of MedSurg and Asia Pacific at Boston Scientific, will retire effective January 1, 2027. He will continue to serve as a senior advisor until February 26, 2027, maintaining his current annual base salary of $780,000.…more
BOSTON SCIENTIFIC CORP
Boston Scientific experienced a cybersecurity incident on August 25, 2026, which disrupted global operations and led the company to determine that it is unlikely to meet its previously provided net sales growth and adjusted EPS guidance for the third quarter and full year 2026. While distribution and manufacturing operations have been substantially restored, the company expects the incident to have a material impact on its 2026 financial results.…more
16 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
Belo Sun Mining Faces Temporary License Suspension for Gold Project
The Brazilian Supreme Court has temporarily suspended the installation license for Belo Sun's Volta Grande Gold Project pending the outcome of a settlement hearing. The project remains subject to judicial approval, maintaining uncertainty regarding its development timeline.…more
●●●●●●●● ●●●●● ●●●●●●
Boston Scientific has appointed Joseph M. Fitzgerald, currently the group president of Cardiovascular, as its new COO effective January 1, 2027. Fitzgerald has been instrumental in driving the company's portfolio growth and innovation within the cardiovascular sector.…more
●●●●●●●● ●●●●● ●●●●●●
Boston Scientific is recalling all Imager II Angiographic Catheters and permanently discontinuing the product line due to a manufacturing defect that poses safety risks. While the company is taking proactive measures, the recall and product discontinuation may impact future revenue.…more
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.